Intraoperative assessment and postsurgical treatment of prostate cancer tumors using tumor-targeted nanoprobes.
heptamethine cyanine
image-guided therapy
iron oxide nanoparticles
near infrared fluorescence imaging
prostate cancer
Journal
Nanotheranostics
ISSN: 2206-7418
Titre abrégé: Nanotheranostics
Pays: Australia
ID NLM: 101698994
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
07
2020
accepted:
13
10
2020
entrez:
4
1
2021
pubmed:
5
1
2021
medline:
2
6
2021
Statut:
epublish
Résumé
Successful visualization of prostate cancer (PCa) tumor margins during surgery remains a major challenge. The visualization of these tumors during surgery via near infrared fluorescence (NIRF) imaging would greatly enhance surgical resection, minimizing tumor recurrence and improving outcome. Furthermore, chemotherapy is typically administered to patients after surgery to treat any missed tumor tissue around the surgical area, minimizing metastasis and increasing patient survival. For these reasons, a theranostics fluorescent nanoparticle could be developed to assist in the visualization of PCa tumor margins, while also delivering chemotherapeutic drug after surgery.
Identifiants
pubmed: 33391975
doi: 10.7150/ntno.50095
pii: ntnov05p0057
pmc: PMC7738944
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
57-72Subventions
Organisme : NIBIB NIH HHS
ID : R01 EB019288
Pays : United States
Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Eur Urol. 2015 Feb;67(2):310-8
pubmed: 24631409
Annu Rev Pharmacol Toxicol. 2012;52:135-51
pubmed: 21854228
Lancet Oncol. 2016 Dec;17(12):1661-1671
pubmed: 27825638
J Clin Oncol. 2011 Jul 1;29(19):2660-6
pubmed: 21606412
Clin Cancer Res. 2016 Mar 15;22(6):1403-12
pubmed: 26490315
Kidney Int. 2017 Jul;92(1):47-66
pubmed: 28434822
JAMA. 2017 Jun 27;317(24):2532-2542
pubmed: 28655021
Future Oncol. 2017 Apr;13(8):755-765
pubmed: 27842445
Clin Cancer Res. 2013 Jul 15;19(14):3745-54
pubmed: 23674494
Mol Cancer Ther. 2011 Dec;10(12):2298-308
pubmed: 21926191
Urology. 2014 Oct;84(4):982.e9-14
pubmed: 25139676
PLoS One. 2011;6(5):e20372
pubmed: 21625523
Nanotheranostics. 2020 Jun 18;4(4):195-200
pubmed: 32637297
Radiology. 2019 Dec;293(3):554-564
pubmed: 31638489
J Magn Reson Imaging. 2015 Apr;41(4):884-98
pubmed: 24974785
Nanotheranostics. 2017 Jul 6;1(3):296-312
pubmed: 29071194
Nano Lett. 2017 Jan 11;17(1):242-248
pubmed: 27966988
J Nucl Med. 2014 Jun;55(6):995-1001
pubmed: 24700882
Oncotarget. 2017 Sep 23;8(50):87891-87902
pubmed: 29152128
AJR Am J Roentgenol. 2015 Sep;205(3):W366-73
pubmed: 26102308
Nucl Med Biol. 2013 Apr;40(3):351-60
pubmed: 23375364
J Clin Oncol. 2008 Aug 20;26(24):4012-21
pubmed: 18711192
Clin Cancer Res. 2014 Feb 1;20(3):617-30
pubmed: 24097861
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Oncologist. 2017 Jan;22(1):25-32
pubmed: 27789775
Pharmacotherapy. 2010 Jan;30(1):70-9
pubmed: 20030475
J Biomed Opt. 2016 May 1;21(5):50901
pubmed: 27165449
Clin Cancer Res. 2017 Jan 15;23(2):330-335
pubmed: 27793960
Radiology. 2017 Nov;285(2):343-356
pubmed: 29045233
Eur Urol. 2014 May;65(5):947-64
pubmed: 23957947
Int J Urol. 2015 Oct;22(10):898-909
pubmed: 26173593
Adv Drug Deliv Rev. 2013 Oct;65(10):1284-98
pubmed: 24018362
N Engl J Med. 2004 Oct 7;351(15):1513-20
pubmed: 15470214
Mol Pharm. 2017 Jan 3;14(1):1-13
pubmed: 26992462
ACS Nano. 2020 Jul 28;14(7):8392-8408
pubmed: 32551496
Cancer Cell. 2013 Mar 18;23(3):332-46
pubmed: 23518348
Oncotarget. 2017 May 24;8(34):56880-56892
pubmed: 28915639
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
Oncotarget. 2014 Oct 30;5(20):10114-26
pubmed: 25361418
Cancer. 2019 Jul 1;125(13):2222-2232
pubmed: 30840322
Sci Transl Med. 2012 Apr 4;4(128):128ra39
pubmed: 22491949
Nat Commun. 2014 Mar 04;5:3384
pubmed: 24594970
Urology. 2017 Aug;106:133-138
pubmed: 28438626
Drug Resist Updat. 2014 Apr;17(1-2):13-23
pubmed: 24853766
Crit Rev Ther Drug Carrier Syst. 2016;33(2):159-93
pubmed: 27651101
J Biol Chem. 2008 Nov 7;283(45):30576-84
pubmed: 18784072
J Drug Deliv. 2013;2013:863539
pubmed: 23431456
Biochem Pharmacol. 2012 Oct 15;84(8):1070-7
pubmed: 22864060
Oncol Lett. 2015 Oct;10(4):2142-2148
pubmed: 26622809
Small. 2009 Aug 17;5(16):1862-8
pubmed: 19384879
Adv Drug Deliv Rev. 2013 Nov;65(13-14):1784-802
pubmed: 23880506
J Clin Oncol. 2011 Sep 20;29(27):3705-14
pubmed: 21860001
Sci Transl Med. 2015 Nov 18;7(314):314ra183
pubmed: 26582898
Phys Med Biol. 2012 May 21;57(10):3123-36
pubmed: 22547491
Actas Urol Esp. 2016 Apr;40(3):190-4
pubmed: 26598421